1445. Impact of 10-valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns among Children Aged <5 Years and Adults with HIV Infection, Kenya 2009–2013
Session: Poster Abstract Session: Pneumococcal Vaccines
Friday, October 5, 2018
Room: S Poster Hall

Background: Kenya introduced 10-valent pneumococcal conjugate vaccine (PCV10) in 2011 (3-doses at ages 6, 10, and 14 weeks). Impact of PCV10 on pneumococcal carriage was unknown in this setting. We assessed changes in pneumococcal carriage and antibiotic susceptibility in children aged <5 years (U5) and HIV-infected adults (HIV+ adults) post-PCV10 introduction.

Methods: During 2009–13, we performed annual cross-sectional pneumococcal carriage surveys in two sites with ongoing population-based surveillance: Kibera (U5 only) and Lwak (U5 and HIV+ adults, catch-up vaccination for children 1-4 years offered in 2011). Nasopharyngeal swabs (and oropharyngeal swabs in adults) were obtained for culture. Pneumococcal isolates were serotyped by multiplex PCR and Quellung. Antibiotic susceptibility was determined (2009 and 2013). We calculated changes in penicillin nonsusceptible (intermediate or resistant) pneumococci (PNSP) carriage by chi-squared test. Changes in PCV10-type (VT) pneumococcal carriage in 2013 compared to baseline (U5: 2009–10, adults: 2009 only) were calculated by modified Poisson regression by age and site.

Results: Overall, 2,962 U5 (2,073 in Kibera, 889 in Lwak) and 2,028 HIV+ adults were enrolled. VT carriage declined by 52-60% in children 1-4 years, by 60% in children <1 year in Kibera, and by 76% in HIV+ adults (Table). PNSP carriage declined from 32.8% to 22.3% (P<.01) in HIV+ adults but did not change in U5 (Kibera: 77.0% vs. 75.5%, P=.10; Lwak: 74.3% vs. 74.6%, P=.94).  

Conclusion: The infant PCV10 program was associated with declines in VT carriage among U5 and HIV+ adults, and declines in PNSP carriage among HIV+ adults; however, VT carriage remained >10% among U5 two years post-PCV10 introduction.

 


Table. PCV10-type carriage by site and age groups

Site

 

Kibera

Lwak

Age Group

Year

Carriage (%)

aPR (95% CI)*

Carriage (%)

aPR (95% CI)*

<1 year

2009-10

38.2

Ref

30.0

Ref

 

2013

14.6

0.40 (0.26, 0.62)

10.3

0.37 (0.11, 1.24)

1–4 years 

2009-10

38.6

Ref

34.3

Ref

 

2013

18.7

0.48 (0.37, 0.62)

13.8

0.40 (0.27, 0.60)

HIV+ adults

2009

12.9

Ref

 

2013

2.8

0.24 (0.14, 0.41)

aPR: adjusted prevalence ratio, CI: confidence interval

*Adjusted for respiratory illness ≤30 days, antibiotic use ≤7 days, and area used for cooking

 

Miwako Kobayashi, MD, MPH1, Lindsay Kim, MD, MPH2, Godfrey Bigogo, MPH3, Daniel Ondari, BA, CM3, Laura Conklin, MD1, Arthur Odoyo, BS3, Herine Odiembo, MPH3, Fabiana Pimenta, PhD4, Dominic Ouma, MPH5, Aaron Harris, MD, MPH6, Kennedy Odero, MA7, Jennifer Milucky, MPH4, Alice Ouma, MSc3, George Aol, MPH3, Allan Audi, MSc3, Clayton Onyango, MSc8, Leonard Cosmas, MPH9, Geofrey Jagero, MSc3, Jennifer Farrar, MPH1, Maria Da Gloria Carvalho, PhD4, Cynthia Whitney, MD, MPH, FIDSA1, Robert F. Breiman, MD, FIDSA10 and Fernanda C. Lessa, MD, MPH4, (1)Centers for Disease Control and Prevention, Atlanta, GA, (2)Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (3)KEMRI, Kisumu, Kenya, (4)Division of Bacterial Diseases, CDC, Atlanta, GA, (5)KEMRI, Nairobi, GA, Kenya, (6)Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, (7)KEMRI/CDC, Nairobi, Kenya, (8)CDC, Kisumu, Kenya, (9)KEMRI, Nairobi, Kenya, (10)Centers for Disease Control and Prevention, Nairobi, Kenya

Disclosures:

M. Kobayashi, None

L. Kim, None

G. Bigogo, None

D. Ondari, None

L. Conklin, None

A. Odoyo, None

H. Odiembo, None

F. Pimenta, None

D. Ouma, None

A. Harris, None

K. Odero, None

J. Milucky, None

A. Ouma, None

G. Aol, None

A. Audi, None

C. Onyango, None

L. Cosmas, None

G. Jagero, None

J. Farrar, None

M. D. G. Carvalho, None

C. Whitney, None

R. F. Breiman, None

F. C. Lessa, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.